gene editing

Moderna lands $100M upfront in deals with Vertex, Chiesi
Moderna lands $100M upfront in deals with Vertex, Chiesi
Fierce Biotech
Moderna Therapeutics
cystic fibrosis
R&D
Vertex Pharmaceuticals
gene editing
Chiesi
Flag link:
Mammoth Biosciences Signs Exclusive Deal For Recently-Discovered Crispr Protein
Mammoth Biosciences Signs Exclusive Deal For Recently-Discovered Crispr Protein
Forbes
Mammoth Biosciences
gene editing
CRISPR
University of California Berkeley
Flag link:
AbbVie cuts Editas CRISPR pact it inherited from Allergan
AbbVie cuts Editas CRISPR pact it inherited from Allergan
Fierce Biotech
Editas Medicine
Allergan
AbbVie
gene editing
CRISPR
Flag link:
CRISPR and Vertex show durability of gene-editing therapy, hoping for one and done treatment
CRISPR and Vertex show durability of gene-editing therapy, hoping for one and done treatment
Fierce Biotech
Vertex Pharmaceuticals
CRISPR Therapeutics
CTX001
gene editing
sickle cell disease
beta thalassemia
Flag link:
Verve Therapeutics Adds $63M to Edit Heart Attack Risk Out of Genes
Verve Therapeutics Adds $63M to Edit Heart Attack Risk Out of Genes
Xconomy
gene editing
Verve Therapeutics
heart attacks
familial hypercholesterolemia
Flag link:
Stanford team deploys CRISPR gene editing to fight COVID-19
Stanford team deploys CRISPR gene editing to fight COVID-19
Fierce Biotech
Stanford University
CRISPR
gene editing
pandemic
COVID-19
Flag link:
Viacyte Adds $27M to Move Ahead Trio of Stem Cell Diabetes Treatments
Viacyte Adds $27M to Move Ahead Trio of Stem Cell Diabetes Treatments
Xconomy
ViaCyte
diabetes
gene editing
stem cells
Flag link:
Here's Why Editas Could Beat Intellia to a CRISPR Therapy
Here's Why Editas Could Beat Intellia to a CRISPR Therapy
Motley Fool
gene editing
CRISPR
Editas Medicine
Intellia
earnings
Flag link:
How CRISPR can help us win the fight against the pandemic
How CRISPR can help us win the fight against the pandemic
MedCity News
CRISPR
gene editing
pandemic
COVID-19
R&D
Flag link:
Sangamo Therapeutics and Biogen Announce Gene-Therapy Deal, Stock up 39%
Sangamo Therapeutics and Biogen Announce Gene-Therapy Deal, Stock up 39%
Motley Fool
Sangamo Therapeutics
Biogen
gene therapy
gene editing
Parkinson's Disease
Alzheimer's disease
Flag link:
FDA Clinical Hold Stops LogicBio’s Gene Editing Study Before It Starts
FDA Clinical Hold Stops LogicBio’s Gene Editing Study Before It Starts
Xconomy
LogicBio Therapeutics
gene editing
clinical trials
methylmalonic acidemia
FDA
Flag link:
Beam Therapeutics IPO Raises $180M After Nearly Doubling Shares Offered
Beam Therapeutics IPO Raises $180M After Nearly Doubling Shares Offered
Xconomy
IPOs
Beam Therapeutics
gene editing
Flag link:
This Start-up Might Be the Next Gene Editing IPO
This Start-up Might Be the Next Gene Editing IPO
Motley Fool
gene editing
Beam Therapeutics
IPOs
CRISPR
Flag link:
Celgene Gave This Tech Back to Editas Medicine, but It Could Prove Valuable
Celgene Gave This Tech Back to Editas Medicine, but It Could Prove Valuable
Motley Fool
Celgene
Editas Medicine
Juno Therapeutics
CRISPR
gene editing
Flag link:
More CRISPR Stock Catalysts Ahead
More CRISPR Stock Catalysts Ahead
Motley Fool
gene editing
CRISPR
Editas Medicine
Intellia Therapeutics
CRISPR Therapeutics
Flag link:
Cellectis gene editing patent upheld in Europe
Cellectis gene editing patent upheld in Europe
Seeking Alpha
gene editing
Europe
Cellectis
patents
Flag link:
Biotech Stock Pops On Promising First In-Human CRISPR Gene-Editing Drug
Biotech Stock Pops On Promising First In-Human CRISPR Gene-Editing Drug
Investors Business Daily
CRISPR Therapeutics
gene editing
CRISPR
beta thalassemia
sickle cell disease
Flag link:
Editas and Celgene sub Juno are tackling hottest immunotherapy cells
Editas and Celgene sub Juno are tackling hottest immunotherapy cells
Endpoints
Editas Medicine
Celgene
Juno Therapeutics
CRISPR
gene editing
immunotherapy
Flag link:
A Look at America’s First CRISPR Clinical Trial
A Look at America’s First CRISPR Clinical Trial
Xtalks
CRISPR
gene editing
clinical trials
Flag link:
First use of CRISPR against cancer in patients clears early safety hurdles
First use of CRISPR against cancer in patients clears early safety hurdles
Stat
gene editing
CRISPR
patient safety
cancer
Flag link:

Pages